Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors.

Abstract excerpt

Phase three clinical trial evidence suggests that colorectal cancers with the KRAS G13D mutation may benefit from EGFR inhibitors, like cetuximab, in contrast to the other most common KRAS mutations. A mechanism to explain why this mutation behaves differently from other KRAS mutations had long been lacking. Two recent studies have reproduced KRAS G13D specific sensitivity to cetuximab in cellular models, and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biophysical Phenomena
• Share to Fluorescence Resonance Energy Transfer